MX2022009905A - Inhibidores de la tirosina?cinasa fgfr para el tratamiento del cancer de vejiga sin invasion muscular de riesgo alto. - Google Patents
Inhibidores de la tirosina?cinasa fgfr para el tratamiento del cancer de vejiga sin invasion muscular de riesgo alto.Info
- Publication number
- MX2022009905A MX2022009905A MX2022009905A MX2022009905A MX2022009905A MX 2022009905 A MX2022009905 A MX 2022009905A MX 2022009905 A MX2022009905 A MX 2022009905A MX 2022009905 A MX2022009905 A MX 2022009905A MX 2022009905 A MX2022009905 A MX 2022009905A
- Authority
- MX
- Mexico
- Prior art keywords
- bladder cancer
- invasive bladder
- muscle invasive
- treatment
- tyrosine kinase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
En el presente documento se describen métodos para tratar el cáncer de vejiga sin invasión muscular de riesgo alto (CVSIM-RA) que comprenden administrar un inhibidor del receptor del factor de crecimiento de fibroblastos (FGFR, por sus siglas en inglés). También se describen métodos para tratar el cáncer de vejiga sin invasión muscular de riesgo intermedio (CVSIM-RI) que comprenden administrar un inhibidor de FGFR.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062975547P | 2020-02-12 | 2020-02-12 | |
US202063018914P | 2020-05-01 | 2020-05-01 | |
US202063118475P | 2020-11-25 | 2020-11-25 | |
PCT/EP2021/053385 WO2021160764A1 (en) | 2020-02-12 | 2021-02-11 | Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022009905A true MX2022009905A (es) | 2022-08-25 |
Family
ID=74666675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022009905A MX2022009905A (es) | 2020-02-12 | 2021-02-11 | Inhibidores de la tirosina?cinasa fgfr para el tratamiento del cancer de vejiga sin invasion muscular de riesgo alto. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230110113A1 (es) |
EP (1) | EP4103185A1 (es) |
JP (1) | JP2023513704A (es) |
KR (1) | KR20220140781A (es) |
CN (1) | CN115103678A (es) |
AU (1) | AU2021220285A1 (es) |
BR (1) | BR112022015827A2 (es) |
CA (1) | CA3162962A1 (es) |
IL (1) | IL295514A (es) |
JO (1) | JOP20220182A1 (es) |
MX (1) | MX2022009905A (es) |
TW (1) | TW202143970A (es) |
WO (1) | WO2021160764A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3235311A1 (en) * | 2021-10-12 | 2023-04-20 | Taris Biomedical Llc | Erdafitinib formulations and systems for intravesical administration |
TW202400174A (zh) * | 2022-02-18 | 2024-01-01 | 美商塔里斯生物醫學有限責任公司 | 用於膀胱內施用的Erdafitinib調配物及滲透系統 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
EP0951541B1 (en) | 1995-07-31 | 2005-11-30 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
MX2007014782A (es) | 2005-05-23 | 2008-02-19 | Novartis Ag | Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona. |
US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
DK3198033T3 (da) | 2014-09-26 | 2022-04-11 | Janssen Pharmaceutica Nv | Anvendelse af mutante fgfr-genpaneler til identificering af kræftpatienter som reagerer på behandling med en fgfr-inhibitor |
JOP20200201A1 (ar) * | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
MA47408B1 (fr) * | 2017-12-20 | 2023-08-31 | Janssen Pharmaceutica Nv | Traitement du cancer |
-
2021
- 2021-02-11 MX MX2022009905A patent/MX2022009905A/es unknown
- 2021-02-11 AU AU2021220285A patent/AU2021220285A1/en active Pending
- 2021-02-11 CN CN202180014162.9A patent/CN115103678A/zh active Pending
- 2021-02-11 IL IL295514A patent/IL295514A/en unknown
- 2021-02-11 JO JOP/2022/0182A patent/JOP20220182A1/ar unknown
- 2021-02-11 JP JP2022548599A patent/JP2023513704A/ja active Pending
- 2021-02-11 US US17/904,139 patent/US20230110113A1/en active Pending
- 2021-02-11 BR BR112022015827A patent/BR112022015827A2/pt unknown
- 2021-02-11 KR KR1020227031209A patent/KR20220140781A/ko unknown
- 2021-02-11 WO PCT/EP2021/053385 patent/WO2021160764A1/en active Application Filing
- 2021-02-11 EP EP21706187.8A patent/EP4103185A1/en active Pending
- 2021-02-11 CA CA3162962A patent/CA3162962A1/en active Pending
- 2021-02-17 TW TW110105372A patent/TW202143970A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
TW202143970A (zh) | 2021-12-01 |
AU2021220285A1 (en) | 2022-10-06 |
BR112022015827A2 (pt) | 2022-10-04 |
EP4103185A1 (en) | 2022-12-21 |
JOP20220182A1 (ar) | 2023-01-30 |
US20230110113A1 (en) | 2023-04-13 |
IL295514A (en) | 2022-10-01 |
WO2021160764A1 (en) | 2021-08-19 |
KR20220140781A (ko) | 2022-10-18 |
JP2023513704A (ja) | 2023-04-03 |
CA3162962A1 (en) | 2021-08-19 |
CN115103678A (zh) | 2022-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20220182A1 (ar) | مثبطات كيناز تيروسين fgfr لعلاج سرطان المثانة الغازي غير العضلي عالي الخطورة | |
CR20220258A (es) | Inhibidores de kras g12c | |
PH12021550296A1 (en) | Substituted indoles and methods of use thereof | |
MX2013004086A (es) | Metodos para inhibir proliferacion celular en cancers accionados por egfr. | |
WO2016161410A3 (en) | Treatment of cancer using inhibitors of tgf-beta and pd-1 | |
MX2022015410A (es) | Inhibidores de las cinasas receptoras del factor de crecimiento de fibroblastos. | |
IL288395A (en) | Mat2a tricyclic inhibitors and methods for use in cancer therapy | |
MX2021003517A (es) | Composiciones de inhibidor de tirosina quinasa, metodos de fabricacion y metodos de uso. | |
CR10188A (es) | Antagonistas de receptor de factor de crecimiento de tipo insulina (igf-ir) como auxiliares para tratamiento de cancer de prostata | |
EP2476427A3 (en) | A method of treating cancer comprising a VEGF-B antagonist | |
EA201170660A1 (ru) | Избирательная для erbb-3 (her3) комбинированная терапия | |
MX2023007793A (es) | Compuestos de indazol como inhibidores de cinasas. | |
JOP20220107A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
PH12021551276A1 (en) | Combination therapy for the treatment of cancer | |
MX2021009426A (es) | Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer. | |
EP3888643A4 (en) | THERAPEUTIC AND PROPHYLACTIC PROCEDURE FOR ENDOCRINE THERAPY TUMORS BY COMBINED USE OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR WITH ENDOCRINE THERAPY | |
MX2021011943A (es) | Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial. | |
MX2022014903A (es) | Tki de egfr para su uso en el tratamiento de cancer de pulmon de celulas no peque?as. | |
MX2022008874A (es) | Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer. | |
EP4097140A4 (en) | USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS TO TREAT CANCER WITH NRG1 FUSIONS | |
JOP20220329A1 (ar) | مضاد مستقبل crf1 لعلاج فرط تنسج الكظر الخلقي | |
MX2022015739A (es) | Inhibidores alostericos de egfr y metodos de uso de estos. | |
MX2022008532A (es) | Inhibidores de hidrocarburo de arilo (ahr) y usos de estos. | |
MX2021012499A (es) | Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos. | |
MX2021012130A (es) | Combinaciones de inhibidores de transcripción e inhibidores de punto de control inmuneitario para el tratamiento de enfermedad. |